Highlights
- Levothyroxine therapy shows minimal overall effect on lipid and cardiometabolic biomarkers in older adults with subclinical hypothyroidism (SCH).
- Potential beneficial lipid and lipoprotein profile changes were observed in individuals with baseline TSH ≥10 mIU/L, warranting further investigation.
- Evidence from randomized controlled trials and meta-analyses indicates levothyroxine’s lipid-lowering effects are more pronounced in younger or milder SCH populations.
- Adjunctive lifestyle interventions like Baduanjin exercise may complement pharmacotherapy by improving lipids and reducing TSH in elderly SCH patients.
Background
Specialty calculators
For clinical reference; use professional judgment.
